Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Daiichi Sankyo
Federal Trade Commission

Generated: December 14, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,453,795

« Back to Dashboard

Which drugs does patent 6,453,795 protect, and when does it expire?


Protection for SPIRIVA RESPIMAT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-nine patent family members in thirty-six countries.

Summary for Patent: 6,453,795

Title: Locking mechanism for a spring-actuated device
Abstract:A spring-actuated output drive device is used for example in medical aerosol therapy for a miniaturised high-pressure producing device for atomising a small dose of a liquid medicament. A locking-stressing-mechanism for such an output d rive device is to be stressed with the application of a relatively small amount of force and is to be released with one hand and is to operate reliably over a prolonged period of time. The locking-stressing-mechanism comprises a force step-up transmission, for example a screw thrust transmission for stressing the spring, an annularly arranged locking member with engaging locking surfaces, two abutments for limiting the travel of the spring and a release button. It is compact, economical to produce, easy to assemble and comprises components with a low rate of wear. It can be reliably and easily handled by unskilled persons, even when high spring forces are involved. A medicament to be atomised can thus be metered with a very high degree of accuracy.
Inventor(s): Eicher; Joachim (Dortmund, DE), Schyra; Michael (Wulfrath, DE), Forster; Richard (Fensterbach, DE)
Assignee: Boehringer Ingelheim International GmbH (DE)
Application Number:09/077,942
Patent Claim Types:
see list of patent claims

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Boehringer IngelheimCOMBIVENT RESPIMATalbuterol sulfate; ipratropium bromideSPRAY, METERED;INHALATION021747-001Oct 7, 2011RXYesYes► Subscribe► Subscribe► SubscribeY
Boehringer IngelheimSPIRIVA RESPIMATtiotropium bromideSPRAY, METERED;INHALATION021936-002Sep 15, 2015RXYesNo► Subscribe► Subscribe► SubscribeY
Boehringer IngelheimSTIOLTO RESPIMATolodaterol hydrochloride; tiotropium bromideSPRAY, METERED;INHALATION206756-001May 21, 2015RXYesYes► Subscribe► Subscribe► SubscribeY
Boehringer IngelheimSTRIVERDI RESPIMATolodaterol hydrochlorideSPRAY, METERED;INHALATION203108-001Jul 31, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
Boehringer IngelheimSPIRIVA RESPIMATtiotropium bromideSPRAY, METERED;INHALATION021936-001Sep 24, 2014RXYesYes► Subscribe► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,453,795

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany195 45 226Dec 05, 1995
Germany195 45 226Dec 5, 1995
PCT Information
PCT FiledDecember 05, 1996PCT Application Number:PCT/EP96/05607
PCT Publication Date:June 12, 1997PCT Publication Number: WO97/20590

International Patent Family for Patent: 6,453,795

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina004849► Subscribe
Austria233112► Subscribe
Australia1194797► Subscribe
Australia716773► Subscribe
Bulgaria102537► Subscribe
Bulgaria63993► Subscribe
Brazil9611878► Subscribe
Canada2237853► Subscribe
China1119181► Subscribe
China1203533► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Farmers Insurance
Federal Trade Commission
Daiichi Sankyo
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: